Bimekizumab treatment in patients with psoriatic arthritis and TNFi-IR: results up to 1 year

To cite: Coates LC, Landewé R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open 2024;10:e003855. doi: 10.1136/rmdopen-2023-003855
Read the full article here: dx.doi.org/10.1...
Objective: To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.
Conclusions: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from weeks 16 to 52.